Publisher's Note

The June 20, 2006 special article by Kris et al entitled, “American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006” (J Clin Oncol 24:2932-2947, 2006) was published online May 22, 2006, with errors.

In Section I, “Emesis Caused By Intravenously Administered Antineoplastic Agents,” the headings under Subsection A, “Vomiting Occurring 0 To 24 Hours After Therapy (Acute Emesis)” should have been numbered as follows:

1. Emetic Risk of Antineoplastic Agents: Emetic Risk Categories
2. Antiemetic Agents: Highest Therapeutic Index
3. Antiemetic Agents: Lower Therapeutic Index—Metoclopramide, Butyrophenones, Phenothiazines, and Cannabinoids
4. Antiemetic Agents: Adjunctive Drugs (benzodiazepines lorazepam, alprazolam and antihistamines diphenhydramine)
5. Antiemetic Agents: Combinations of Antiemetics
6. Recommendations for Specific Emetic Risk Categories

In Table 7, under “Antiemetic Regimens and Schedules,” Dexamethasone was scheduled on days 1, 2 and 3 for “High” emetic risk, and should have been given on days 1–4. Also, Dexamethasone was scheduled on day 1 only for “Moderate” emetic risk, and should have been listed as continuing on days 2 and 3 when aprepitant is not given.

In Table 8, under “Single Dose Administered Before Chemotherapy,” “Oral: 12 mg (with aprepitant)” and “Oral: 20 mg” were listed for Dexamethasone, while it should have read, “Oral: 12 mg” only. Under “Single Dose Administered Daily,” “Oral: 8 mg days 2, 3” was listed for Dexamethasone, while it should have read, “Oral: 8 mg days 2–4.” Also, “Dexamethasone” should have been left-justified as a row heading.

On page 2937, the second sentence of the last paragraph was given as: “In the trials in patients receiving cisplatin, dexamethasone was also administered at a reduced dosage of 8 mg once daily on days 2 and 3.^33,34”

While it should have read:
“In the trials in patients receiving cisplatin, dexamethasone was also administered at a reduced dosage of 8 mg once daily on days 2 to 4.^33,34”

In Table 9, under “Dexamethasone,” both 8 mg doses should have been listed as “without aprepitant.”

On page 2938, the second sentence of the second to last paragraph was given as: “Overall, vomiting prevention was improved by 9% (P = .015) for the 5-day period after chemotherapy with the three-drug regimen of aprepitant, ondansetron, and dexamethasone, over the standard combination of ondansetron and dexamethasone alone.”

While it should have read:
“Complete response was improved by 9% (P = .015) for the 5-day period after chemotherapy with the three-drug regimen of aprepitant, ondansetron, and dexamethasone, over the standard combination of ondansetron and dexamethasone alone."³⁹

The sentence beginning on page 2938 and continuing on page 2939 was given as: “The Panel cautions that the recommendation to use a lower dose of dexamethasone when administered as an antiemetic with aprepitant does not apply to the use of prednisone, dexamethasone, or any corticosteroid when administered as an anticancer therapy (ie, as part of cyclophosphamide, doxorubicin, vincristine, prednisone CHOP or cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimens).”

While it should have read:
“The Panel cautions that the recommendation to use a lower dose of dexamethasone when administered as an antiemetic with aprepitant does not apply to the use of prednisone, dexamethasone, or any corticosteroid when administered as an anticancer therapy (ie, as part of cyclophosphamide, doxorubicin, vincristine, prednisone CHOP-based or mechlorethamine, vincristine, procarbazine, and prednisone MOPP chemotherapy regimens).”

All corrections have been made as of October 20, 2006.